BRPI1014978A2 - método de tratamento do câncer e composição farmacêutica. - Google Patents

método de tratamento do câncer e composição farmacêutica.

Info

Publication number
BRPI1014978A2
BRPI1014978A2 BRPI1014978-3A BRPI1014978A BRPI1014978A2 BR PI1014978 A2 BRPI1014978 A2 BR PI1014978A2 BR PI1014978 A BRPI1014978 A BR PI1014978A BR PI1014978 A2 BRPI1014978 A2 BR PI1014978A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treatment method
cancer treatment
cancer
medicaments
Prior art date
Application number
BRPI1014978-3A
Other languages
English (en)
Inventor
S. Basu Hirak
Zarling David
Original Assignee
Colby Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014978(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colby Pharmaceutical Company filed Critical Colby Pharmaceutical Company
Publication of BRPI1014978A2 publication Critical patent/BRPI1014978A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método de tratamento do câncer e composição farmacêutica são descritas aqui composições farmacêuticas e medicamentos, e métodos de usar tais composições farmacêuticas e medicamentos no tratamento da inflamação e câncer.
BRPI1014978-3A 2009-04-17 2010-04-16 método de tratamento do câncer e composição farmacêutica. BRPI1014978A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17055509P 2009-04-17 2009-04-17
US61/170,555 2009-04-17
PCT/US2010/031455 WO2010121177A2 (en) 2009-04-17 2010-04-16 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses

Publications (1)

Publication Number Publication Date
BRPI1014978A2 true BRPI1014978A2 (pt) 2019-07-02

Family

ID=42983172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014978-3A BRPI1014978A2 (pt) 2009-04-17 2010-04-16 método de tratamento do câncer e composição farmacêutica.

Country Status (16)

Country Link
US (1) US20100297262A1 (pt)
EP (1) EP2419095A4 (pt)
JP (2) JP2012524074A (pt)
KR (1) KR20120008056A (pt)
CN (1) CN102438615A (pt)
AP (1) AP2011005974A0 (pt)
AU (1) AU2010236203A1 (pt)
BR (1) BRPI1014978A2 (pt)
CA (1) CA2756820A1 (pt)
CL (1) CL2011002595A1 (pt)
CR (1) CR20110599A (pt)
IL (1) IL215847A0 (pt)
MX (1) MX2011010956A (pt)
SG (1) SG175251A1 (pt)
WO (1) WO2010121177A2 (pt)
ZA (1) ZA201108369B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853277B2 (en) 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US8816071B2 (en) * 2011-12-02 2014-08-26 First Tech International Limited Tocotrienol derivatives and associated methods
EP2935583B1 (en) * 2012-12-20 2018-09-12 General Electric Company Formulations for nucleic acid stabilization on solid substrates
US9896466B2 (en) * 2013-04-24 2018-02-20 Kkcg Ag Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
WO2018193114A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
WO2018193113A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Phosphonium-ion tethered tetracycline drugs for treatment of cancer
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
WO2019113210A1 (en) * 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US20210037855A1 (en) * 2018-03-29 2021-02-11 Dsm Ip Assets B.V. Use of twin-chromanols as antioxidants
WO2019185939A1 (en) * 2018-03-29 2019-10-03 Dsm Ip Assets B.V. Use of twin-chromanols as antioxidants in oil
CN114901290B (zh) * 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
CN110980915B (zh) * 2019-12-23 2022-08-02 解冰 一种纳米氧自由基水在抗癌药物中的应用
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Ｔｒａｐ１阻害剤およびその用途
CN117442601B (zh) * 2023-10-31 2024-05-28 上海市东方医院（同济大学附属东方医院） 一种磷酸酶抑制剂类似物BX-金属NPs及其制备方法和应用
CN117298130B (zh) * 2023-11-17 2024-10-25 河南工业大学 一种级联氧化应激增强的壳寡糖-阿霉素生物材料及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0669132A1 (en) * 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
DE69515842T2 (de) * 1995-04-07 2000-11-02 Sanofi-Synthelabo, Paris Kombinationspräparat von Acetylsalicylat von Lysin, Vitamine E und Beta-Karotin
US20080275005A1 (en) * 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
KR20040058192A (ko) * 2001-10-19 2004-07-03 맥심 파마수티컬즈 인크. 간 질환 치료용으로서의 히스타민 용도
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040102421A1 (en) * 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments
US7326734B2 (en) * 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers
CN102349927A (zh) * 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
EP1719508A1 (en) * 2005-05-06 2006-11-08 Yih-Lin Chung Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction
US20070161609A1 (en) * 2006-01-10 2007-07-12 Charles Buck Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease
US20080032940A1 (en) * 2006-08-07 2008-02-07 Balaraman Kalyanaraman Methods for reducing anthracycline-induced toxicity
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合

Also Published As

Publication number Publication date
CR20110599A (es) 2012-02-09
SG175251A1 (en) 2011-11-28
EP2419095A4 (en) 2012-12-05
WO2010121177A2 (en) 2010-10-21
JP2012524074A (ja) 2012-10-11
IL215847A0 (en) 2012-01-31
WO2010121177A3 (en) 2011-03-31
CL2011002595A1 (es) 2013-10-04
CA2756820A1 (en) 2010-10-21
US20100297262A1 (en) 2010-11-25
JP2015172066A (ja) 2015-10-01
MX2011010956A (es) 2012-01-27
AU2010236203A1 (en) 2011-10-13
AP2011005974A0 (en) 2011-12-31
EP2419095A2 (en) 2012-02-22
KR20120008056A (ko) 2012-01-25
CN102438615A (zh) 2012-05-02
ZA201108369B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
BRPI1014978A2 (pt) método de tratamento do câncer e composição farmacêutica.
CY1119892T1 (el) Φορεις και αλληλουχιες για την αγωγη ασθενειων
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
TW200800994A (en) Inhibitors of E1 activating enzymes
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TW200806280A (en) Pharmaceutical compositions
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA200900285A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
TN2012000170A1 (en) Compositions for treating centrally mediated nausea and vomiting
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
ATE528013T1 (de) Impfstoff-zusammensetzungen
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
MX2010003045A (es) Composiciones de ciclosporina.
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]